Abstract
Abstract The potential of blood tests for multi-cancer early detection (MCED) to reduce cancer mortality has elicited both optimism and concern about their generalized applicability. Identifying in the general population individuals at increased risk, through the use of biomarkers together with subject characteristics, has the potential to trigger preventive intervention and to improve effectiveness of early detection through a tailored approach to screening based on a personalized risk profile. The contribution of blood-based biomarkers for personalized lung cancer risk assessment will be highlighted. Citation Format: Samir Hanash. Contribution of biomarker-based risk profiles to cancer early detection. [abstract]. In: Proceedings of the AACR Special Conference: Precision Prevention, Early Detection, and Interception of Cancer; 2022 Nov 17-19; Austin, TX. Philadelphia (PA): AACR; Can Prev Res 2023;16(1 Suppl): Abstract nr IA021.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
